Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 88Carcinoma, Non-Small-Cell Lung 86Multiple Myeloma 73Prostatic Neoplasms 63Neoplasms 55Colorectal Neoplasms 46Lymphoma 42Squamous Cell Carcinoma of Head and Neck 41Leukemia, Myeloid, Acute 41Lung Neoplasms 39Pancreatic Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 31Ovarian Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Carcinoma, Renal Cell 29Urinary Bladder Neoplasms 28Lymphoma, Non-Hodgkin 27Melanoma 26Head and Neck Neoplasms 26Hematologic Neoplasms 25Triple Negative Breast Neoplasms 24Sarcoma 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Hodgkin Disease 23Leukemia, Lymphocytic, Chronic, B-Cell 22Glioma 22Stomach Neoplasms 20Myelodysplastic Syndromes 20Lymphoma, Mantle-Cell 19

Interventions

enzalutamide 2inavolisib 1abiraterone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-Resistant Prostate Cancer × 30 days × Clear all
NCT04986423 2026-05-08

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Zenith Epigenetics

Phase 2 Recruiting
200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT07287150 2026-05-06

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡